These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Tumor M2-PK levels in haematological malignancies.
    Author: Oremek GM, Rox S, Mitrou P, Sapoutzis N, Sauer-Eppel H.
    Journal: Anticancer Res; 2003; 23(2A):1135-8. PubMed ID: 12820361.
    Abstract:
    Circulating Tumor M2-PK serum levels were measured in 118 patients with various haematological malignancies. Using 17.5 U/ml as the cut-off level, elevated Tumor M2-PK concentrations were found in 7 out of 35 patients with acute myelocytic leukaemia, 17 out of 38 patients with chronic myelocytic leukaemia, 5 out of 18 patients with chronic lymphocytic leukaemia and in 6 out of 14 patients with acute lymphocytic leukaemia. Only 9 out of 195 healthy control individuals had Tumor M2-PK plasma levels above 17.5 U/ml. Serial determinations of Tumor M2-PK were performed in 3 patients with haematological malignancies during chemotherapy. Disease regression was associated with alternating Tumor M2-PK plasma levels. Thus, Tumor M2-PK is not a useful indicator of haematological malignancies. Moreover, serial Tumor M2-PK measurement may be insignificant in monitoring response to chemotherapy in these patients.
    [Abstract] [Full Text] [Related] [New Search]